Literature DB >> 22231232

RA in 2011: Advances in diagnosis, treatment and definition of remission.

Gerd R Burmester1.   

Abstract

Evidence presented in 2011 suggests that rheumatoid arthritis might comprise two separate diseases—each with different etiological underpinnings—and that kinase inhibitors could soon be added to the therapeutic armamentarium. Together with new definitions of remission, these advances could aid the development of personalized, treat-to-target strategies.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22231232     DOI： 10.1038/nrrheum.2011.201

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


  10 in total

1.  Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci.

Authors:  Eli A Stahl; Soumya Raychaudhuri; Elaine F Remmers; Gang Xie; Stephen Eyre; Brian P Thomson; Yonghong Li; Fina A S Kurreeman; Alexandra Zhernakova; Anne Hinks; Candace Guiducci; Robert Chen; Lars Alfredsson; Christopher I Amos; Kristin G Ardlie; Anne Barton; John Bowes; Elisabeth Brouwer; Noel P Burtt; Joseph J Catanese; Jonathan Coblyn; Marieke J H Coenen; Karen H Costenbader; Lindsey A Criswell; J Bart A Crusius; Jing Cui; Paul I W de Bakker; Philip L De Jager; Bo Ding; Paul Emery; Edward Flynn; Pille Harrison; Lynne J Hocking; Tom W J Huizinga; Daniel L Kastner; Xiayi Ke; Annette T Lee; Xiangdong Liu; Paul Martin; Ann W Morgan; Leonid Padyukov; Marcel D Posthumus; Timothy R D J Radstake; David M Reid; Mark Seielstad; Michael F Seldin; Nancy A Shadick; Sophia Steer; Paul P Tak; Wendy Thomson; Annette H M van der Helm-van Mil; Irene E van der Horst-Bruinsma; C Ellen van der Schoot; Piet L C M van Riel; Michael E Weinblatt; Anthony G Wilson; Gert Jan Wolbink; B Paul Wordsworth; Cisca Wijmenga; Elizabeth W Karlson; Rene E M Toes; Niek de Vries; Ann B Begovich; Jane Worthington; Katherine A Siminovitch; Peter K Gregersen; Lars Klareskog; Robert M Plenge
Journal:  Nat Genet       Date:  2010-05-09       Impact factor: 38.330

2.  2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Authors:  Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovsky; Frederick Wolfe; Gillian Hawker
Journal:  Ann Rheum Dis       Date:  2010-09       Impact factor: 19.103

3.  Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.

Authors:  Roy Fleischmann; Maurizio Cutolo; Mark C Genovese; Eun Bong Lee; Keith S Kanik; Seth Sadis; Carol A Connell; David Gruben; Sriram Krishnaswami; Gene Wallenstein; Bethanie E Wilkinson; Samuel H Zwillich
Journal:  Arthritis Rheum       Date:  2012-03

4.  An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.

Authors:  Michael E Weinblatt; Arthur Kavanaugh; Mark C Genovese; Theresa K Musser; Elliott B Grossbard; Daniel B Magilavy
Journal:  N Engl J Med       Date:  2010-09-22       Impact factor: 91.245

5.  Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis.

Authors:  N B Klarenbeek; R Koevoets; D M F M van der Heijde; A H Gerards; S Ten Wolde; P J S M Kerstens; T W J Huizinga; B A C Dijkmans; C F Allaart
Journal:  Ann Rheum Dis       Date:  2011-08-03       Impact factor: 19.103

6.  Remission of rheumatoid arthritis in clinical practice: application of the American College of Rheumatology/European League Against Rheumatism 2011 remission criteria.

Authors:  Shadi H Shahouri; Kaleb Michaud; Ted R Mikuls; Liron Caplan; Timothy S Shaver; James D Anderson; David N Weidensaul; Ruth E Busch; Shirley Wang; Frederick Wolfe
Journal:  Arthritis Rheum       Date:  2011-11

7.  Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.

Authors:  Katerina Chatzidionysiou; Elisabeth Lie; Evgeny Nasonov; Galina Lukina; Merete Lund Hetland; Ulrik Tarp; Cem Gabay; Piet L C M van Riel; Dan C Nordström; Juan Gomez-Reino; Karel Pavelka; Matija Tomsic; Tore K Kvien; Ronald F van Vollenhoven
Journal:  Ann Rheum Dis       Date:  2011-05-12       Impact factor: 19.103

8.  American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.

Authors:  David T Felson; Josef S Smolen; George Wells; Bin Zhang; Lilian H D van Tuyl; Julia Funovits; Daniel Aletaha; Cornelia F Allaart; Joan Bathon; Stefano Bombardieri; Peter Brooks; Andrew Brown; Marco Matucci-Cerinic; Hyon Choi; Bernard Combe; Maarten de Wit; Maxime Dougados; Paul Emery; Daniel Furst; Juan Gomez-Reino; Gillian Hawker; Edward Keystone; Dinesh Khanna; John Kirwan; Tore K Kvien; Robert Landewé; Joachim Listing; Kaleb Michaud; Emilio Martin-Mola; Pamela Montie; Theodore Pincus; Pamela Richards; Jeffrey N Siegel; Lee S Simon; Tuulikki Sokka; Vibeke Strand; Peter Tugwell; Alan Tyndall; Desirée van der Heijde; Suzan Verstappen; Barbara White; Frederick Wolfe; Angela Zink; Maarten Boers
Journal:  Ann Rheum Dis       Date:  2011-03       Impact factor: 19.103

9.  A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis.

Authors:  Leonid Padyukov; Mark Seielstad; Rick T H Ong; Bo Ding; Johan Rönnelid; Maria Seddighzadeh; Lars Alfredsson; Lars Klareskog
Journal:  Ann Rheum Dis       Date:  2010-12-14       Impact factor: 19.103

10.  Treating rheumatoid arthritis to target: recommendations of an international task force.

Authors:  Josef S Smolen; Daniel Aletaha; Johannes W J Bijlsma; Ferdinand C Breedveld; Dimitrios Boumpas; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Maarten de Wit; Maxime Dougados; Paul Emery; Alan Gibofsky; Juan Jesus Gomez-Reino; Boulos Haraoui; Joachim Kalden; Edward C Keystone; Tore K Kvien; Iain McInnes; Emilio Martin-Mola; Carlomaurizio Montecucco; Monika Schoels; Désirée van der Heijde; Desirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-03-09       Impact factor: 19.103
  10 in total
  4 in total

1.  Novel treatment for refractory rheumatoid arthritis with total glucosides of paeony and nobiletin codelivered in a self-nanoemulsifying drug delivery system.

Authors:  Biao Qu; Xiao-Lin Wang; De-Chong Zheng; Chu-Tian Mai; Zhong-Qiu Liu; Hua Zhou; Ying Xie
Journal:  Acta Pharmacol Sin       Date:  2021-12-06       Impact factor: 7.169

2.  Can rheumatoid arthritis ever cease to exist: a review of various therapeutic modalities to maintain drug-free remission?

Authors:  Di Liu; Na Yuan; Guimei Yu; Ge Song; Yan Chen
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

3.  Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry.

Authors:  Pavel Horák; Martina Skácelová; Karel Hejduk; Andrea Smržová; Karel Pavelka
Journal:  Clin Rheumatol       Date:  2013-06-02       Impact factor: 2.980

4.  Switching from TNFα inhibitor to tacrolimus as maintenance therapy in rheumatoid arthritis after achieving low disease activity with TNFα inhibitors and methotrexate: 24-week result from a non-randomized, prospective, active-controlled trial.

Authors:  Sang Youn Jung; Jung Hee Koh; Ki-Jo Kim; Yong-Wook Park; Hyung-In Yang; Sung Jae Choi; Jisoo Lee; Chan-Bum Choi; Wan-Uk Kim
Journal:  Arthritis Res Ther       Date:  2021-07-08       Impact factor: 5.156
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.